Fresenius Medical: High Yield, Utilities-Like Stock At Valuation Lows

Impact · against what's priced in

Fresenius Medical is positioned as a defensive, high-yield play with improving margins via the FME25+ program. The combination of regulated pricing and aggressive capital returns suggests an undervalued profile relative to its stability.

FMS+0.60

No priced-in read yet

In context

Recovering profitability from FME25+ cost savings and strong free cash flow supporting buybacks and dividends provide a catalyst for valuation expansion.

Read from the article alone

• cash flow
• healthcare
• dividends
• FMS
• buybacks
• defensive stocks
• dialysis

Search tags